Institut Curie, Psycho-Oncology Unit, 26, rue d'Ulm, F - 75231 Paris Cedex 05 France.
Expert Rev Pharmacoecon Outcomes Res. 2002 Dec;2(6):597-606. doi: 10.1586/14737167.2.6.597.
For many years, medical research has focused on 'hard' end-points, such as survival or time to progression, when evaluating research in cancer clinical trials. However, over recent years more recognition has been given to 'softer' end-points, such as quality of life and treatment satisfaction. In many respects, research into treatment satisfaction is in its early stages of development, but we are already beginning to understand that patients' treatment satisfaction can provide great insights into the management of cancer patients. In our review, we discuss the specific conceptual and methodological issues we face when assessing treatment satisfaction in cancer clinical trials and critically review earlier studies of cancer treatment satisfaction.
多年来，医学研究一直集中在评估癌症临床试验的“硬终点”上，如生存或进展时间。然而，近年来，人们对“软终点”的认识越来越多，如生活质量和治疗满意度。在许多方面，治疗满意度的研究还处于起步阶段，但我们已经开始明白，患者的治疗满意度可以为癌症患者的管理提供重要的见解。在我们的综述中，我们讨论了在评估癌症临床试验中的治疗满意度时所面临的具体概念和方法问题，并批判性地回顾了早期的癌症治疗满意度研究。
